DISCLOSURE OF SHAREHOLDINGS IN ACCORDANCE WITH STOCK MARKET RULES

More
BigChartsVirtual Stock ExchangeFiLife.comWSJ AsiaWSJ EuropeWSJ AmericasWSJ ChineseFinancial News OnlineSEARCH
Choose a quote match or "go" to get quote










Choose a topic to search news:










close


Welcome, please sign in.

My Portfolio • Community • VSE • Alerts

Front PageNews & Commentary
Markets
Mutual Funds & ETFs
Personal Finance
Technology
Tools & Research
My MarketWatch
Community
Video
News & Commentary
Columnists First Take Special ReportsHow to Buy
Trading Strategies
The Heat is On
Hong Kong
The Short Sellers
Beijing Olympics 2008
A Growing Hunger
Dubai
Blogs Podcasts Industry NewsTechnology
Health Care
Retail
Automobiles
Economy & PoliticsFed
The Election
NewslettersGuru's Corner
Directory
Hulbert Financial Digest
Election 2008

latest news [HTZ] Hertz Q2 revenue $2.28 bln vs $2.18 bln
Disclosure of Shareholdings in Accordance with Stock Market Rules


Last update: 12:16 p.m. EDT Aug. 7, 2008
GENEVA, SWITZERLAND, Aug 07, 2008 (MARKET WIRE via COMTEX) -- Addex Pharmaceuticals (SWISS: ADXN) announced today that on August 6, 2008, Varuma AG, Aeschenvorstadt 55, 4051 Basel, Switzerland, has informed of exceeding the threshold of 3% in the shareholding of Addex Pharmaceuticals Ltd., holding a total of 231,425 registered shares, corresponding to 3.95% of the voting rights. The beneficiary of the shareholdings of Varuma AG is Mr. Rudolf Maag, at Neuhofweg 11, 4102 Binningen, Switzerland.

NOTE: ADDEX IS A WELL KNOWN PHARMACEUTICAL COMPANY.
About Addex
Addex Pharmaceuticals discovers and develops allosteric modulators for human health. Allosteric modulators are an emerging class of orally available small molecule therapeutic agents that we believe will offer patients better results than classical drugs. Most marketed drugs bind receptors where the body's own natural molecular activators (i.e. endogenous ligands) bind, specifically to a key part of each receptor's anatomy called the "active site". In short, most drugs must out-compete endogenous ligands for the active site. By contrast, allosteric modulators are non-competitive because they bind receptors and modify their function even if the endogenous ligand also is binding it. In addition, because of this, allosteric modulators aren't limited to simply turning a receptor on or off, the way most drugs are. Instead, they act more like a dimmer switch, offering control over the degree of activation or deactivation, while offering the body the ability to maintain control over initiating receptor activation. Furthermore, the allosteric approach generally affords freedom to operate - even on well-known, clinically validated targets - because the intellectual property surrounding allosteric chemistry and the allosteric sites on receptors is most often un-exploited.
ADX10059, our most advanced product, is an mGluR5 NAM (metabotropic glutamate receptor 5 negative allosteric modulator). It has demonstrated clinically and statistically significant efficacy in separate Phase IIa clinical trials in gastroesophageal reflux disease (GERD) patients and migraine headache patients and has potential in additional indications.
The Addex allosteric modulation discovery and development platform have been additionally validated through three seperatate product license or collaboration agreements with Merck & Co., Inc. and Johnson & Johnson as well as investments by Roche Ventures and SR One, the venture investment arm of GlaxoSmithKline. Contacts
Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "not approvable", "continue", "believes", "believe", "will", "remained open to exploring", "would", "could", or similar expressions, or by express or implied discussions regarding Addex Pharmaceuticals Ltd, its business, the potential approval of its products by regulatory authorities, or regarding potential future revenues from such products. Such forward- looking statements reflect the current views of Addex Pharmaceuticals Ltd regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGluR4, mGluR2 or mGluR5 will be approved for sale in any market or by any regulatory authority. Nor can there be any guarantee that allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets will achieve any particular levels of revenue (if any) in the future. In particular, management's expectations regarding allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets could be affected by, among other things, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Pharmaceuticals is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Copyright Copyright Hugin AS 2008. All rights reserved.
Chris Maggos
Head of IR & Communications
Addex Pharmaceuticals
+41 22 884 15 11
Email Contact



SOURCE: Addex Pharmaceuticals
http://www2.marketwire.com/mw/emailprcntct?id=07E63FA2DB9FD852

Copyright 2008 Market Wire, All rights reserved.
Top stories
21 minutes ago Shanghai stocks drop ahead of Olympics ceremony
10:30 PM 8/7/08 Rackspace prices IPO at $12.50 a share
2:37 PM 8/7/08 General obligation bonds have edge over other tax-free munis



Real Estate Weekly E-newsletter Real estate news and commentary from our Personal Finance staff every week.
Sign up

Privacy policy
Most Popular
READE-MAILEDEDITOR'S PICK
Long-time Bear Granville turns bullish
U.S. stocks end steeply down as financials shake up market
U.S. workers must unite to protect their 401(k) savings
Supply and demand turned upside down as commodities plunge
U.S. stock futures drops on AIG loss, Wal-Mart view
Oil futures end losing streak on pipeline shutdown
AIG shares drop by record 18% after 'horrific' results
CORRECT: Pending home sales index rises 5.3% in June: NAR
Citi to settle charges on auction-rate securities
Media's self-censorship over Edwards is bigger scandal
Why McCain would be a mediocre president
U.S. workers must unite to protect their 401(k) savings
Supply and demand turned upside down as commodities plunge
Media's self-censorship over Edwards is bigger scandal
CORRECT: Pending home sales index rises 5.3% in June: NAR
Long-time Bear Granville turns bullish
Citi to settle charges on auction-rate securities
Global coal demand is swelling and these companies will benefit
AIG shares drop by record 18% after 'horrific' results
Decoding the latest business buzzwords
Shanghai stocks drop ahead of Olympics ceremony
Rackspace prices IPO at $12.50 a share
General obligation bonds have edge over other tax-free munis
Why McCain would be a mediocre president
Cathay Pacific posts loss on high fuel prices
Get the Latest MarketWatch News >>
PARTNER CENTER

Site Index | Topics | Archive | Help | Feedback | Media Archive | Premium Products | Mobile | RSS | Podcasts | Company Info | Advertising Media Kit | DJ Client Solutions
The Wall Street Journal Digital Network:
WSJ.com | Barron's Online | BigCharts | Virtual Stock Exchange | All Things Digital | MarketWatch Community
RealEstateJournal.com | Financial News Online | WSJ.com Small Business


Copyright © 2008 MarketWatch, Inc. All rights reserved.
By using this site, you agree to the Terms of Service and Privacy Policy . Disclosure of Shareholdings in Accordance with Stock Market Rules - MarketWatchIntraday data provided by Interactive Data Real Time Services, a division of Interactive Data Corp. and subject to terms of use. Historical and current end-of-day data provided by Interactive Data Pricing and Reference Data. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Dow Jones Indexes(SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by Comstock and is at least 60-minutes delayed. All quotes are in local exchange time. Real-time last sale data provided by NASDAQ.